Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease.
Chevalier G, Laveissière A, Desachy G, Barnich N, Sivignon A, Maresca M, Nicoletti C, Di Pasquale E, Martinez-Medina M, Simpson KW, Yajnik V, Sokol H; MOBIDIC Study Investigators; Plassais J, Strozzi F, Cervino A, Morra R, Bonny C. Chevalier G, et al. Among authors: sokol h. Microbiome. 2021 Aug 23;9(1):176. doi: 10.1186/s40168-021-01135-5. Microbiome. 2021. PMID: 34425887 Free PMC article.
Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease.
Rajca S, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Paintaud G, Piver E, Allez M, Mary JY, Sokol H, Colombel JF, Seksik P. Rajca S, et al. Among authors: sokol h. Inflamm Bowel Dis. 2014 Jun;20(6):978-86. doi: 10.1097/MIB.0000000000000036. Inflamm Bowel Dis. 2014. PMID: 24788220 Clinical Trial.
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Bouhnik Y; Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif. Amiot A, et al. Clin Gastroenterol Hepatol. 2016 Nov;14(11):1593-1601.e2. doi: 10.1016/j.cgh.2016.02.016. Epub 2016 Feb 22. Clin Gastroenterol Hepatol. 2016. PMID: 26917043
Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.
Martineau C, Flourié B, Wils P, Vaysse T, Altwegg R, Buisson A, Amiot A, Pineton de Chambrun G, Abitbol V, Fumery M, Hébuterne X, Viennot S, Laharie D, Beaugerie L, Nancey S, Sokol H; Goli-Crohn Study Group. Martineau C, et al. Among authors: sokol h. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1077-1084. doi: 10.1111/apt.14371. Epub 2017 Oct 13. Aliment Pharmacol Ther. 2017. PMID: 29027693
Enterobacteriaceae are essential for the modulation of colitis severity by fungi.
Sovran B, Planchais J, Jegou S, Straube M, Lamas B, Natividad JM, Agus A, Dupraz L, Glodt J, Da Costa G, Michel ML, Langella P, Richard ML, Sokol H. Sovran B, et al. Among authors: sokol h. Microbiome. 2018 Sep 1;6(1):152. doi: 10.1186/s40168-018-0538-9. Microbiome. 2018. PMID: 30172257 Free PMC article.
414 results